医学
内科学
相对风险
安慰剂
胃肠病学
溃疡性结肠炎
炎症性肠病
荟萃分析
随机对照试验
临床试验
克罗恩病
置信区间
疾病
病理
替代医学
作者
Virginia Solitano,Sudheer K. Vuyyuru,John K MacDonald,Alexa Zayadi,Claire E Parker,Neeraj Narula,Laurent Peyrin–Biroulet,Silvio Danese,Brian G. Feagan,Siddharth Singh,Christopher Ma,Vipul Jairath
出处
期刊:Journal of Crohn's and Colitis
[Oxford University Press]
日期:2023-06-15
卷期号:17 (11): 1800-1816
被引量:8
标识
DOI:10.1093/ecco-jcc/jjad100
摘要
Abstract Background and Aims Oral small-molecule drugs [SMDs] are expanding the therapeutic landscape for inflammatory bowel disease [IBD]. This systematic review and meta-analysis summarizes the efficacy and safety of JAK inhibitor [JAKi] and sphingosine-1-phosphate [S1P] receptor modulator treatments for ulcerative colitis [UC] and Crohn’s disease [CD]. Methods MEDLINE, Embase, and CENTRAL were searched from inception to May 30, 2022. Randomized controlled trials [RCTs] of JAKi and S1P receptor modulators in adults with UC or CD were eligible. Clinical, endoscopic, histological, and safety data were pooled and analysed using a random-effects model. Results Thirty-five RCTs [26 UC, nine CD] were included. In UC, JAKi therapy was associated with induction of clinical (risk ratio [RR] 3.16, 95% confidence interval [CI] 2.03–4.92; I2 = 65%) and endoscopic [RR 3.99, 95% CI 2.36–6.75; I2 = 36%] remission compared to placebo. Upadacitinib was associated with histological response [RR 2.63, 95% CI 1.97–3.53]. S1P modulator therapy was associated with induction of clinical [RR 2.52, 95% CI 1.88–3.39; I2 = 1%] and endoscopic [RR 2.39, 95% CI 1.07–5.33; I2 = 0%] remission relative to placebo. Ozanimod was superior to placebo for inducing histological remission in UC [RR 2.20, 95% CI 1.43–3.37; I2 = 0%], while etrasimod was not [RR 2.36, 95% CI 0.71–7.88; I2 = 0%]. In CD, JAKi therapy was superior to placebo for induction of clinical remission [RR 1.53, 95% CI 1.19–1.98; I2 = 31%], and endoscopic remission [RR 4.78, 95% CI 1.63–14.06; I2 = 43%] compared to placebo. The risk of serious infections was similar for oral SMDs and placebo. Conclusion JAKi and S1P receptor modulator therapies are effective in IBD for inducing clinical and endoscopic remission and, in some circumstances, histological response.
科研通智能强力驱动
Strongly Powered by AbleSci AI